FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all ...

Ipsen SA (IPSEF) reports robust financial performance with a 9.9% sales increase and strategic pipeline developments, despite ...

Q4 2024 Management View CEO David Loew emphasized Ipsen’s sustained growth in 2024, with total sales increasing by 9.9%. He highlighted the strong performance of the ex-Somatuline portfolio, which ...

Shares of Ipsen (EPA:IPN) dropped 2.7% as the market reacted to the company's mixed fourth-quarter results. Despite reporting ...

A former executive at French drugmaker Ipsen was sentenced on Thursday to two months in a U.S. prison for illegally trading ...

UBS analyst Xian Deng maintained a Buy rating on Ipsen (0MH6 – Research Report) today and set a price target of €145.00. The company’s shares ...

In a report released on February 11, Justine Telliez from Kepler Capital maintained a Hold rating on Ipsen (0MH6 – Research Report), with a ...

French drugmaker Ipsen today released final results from the Phase III CheckMate -9ER trial of Cabometyx (cabozantinib) in ...

Ipsen has taken rights to PPAR agonist elafibranor as a treatment for primary biliary cholangitis – a chronic, autoimmune disease in which bile ducts in the liver are gradually destroyed causing ...

Ipsen is a growing biopharma company that combines a dynamic, biotech mindset with the resources that come from having 5,400 employees and a direct presence in more than 30 countries. This ...

Ipsen has suffered a setback in its marathon effort to bring palovarotene to market for ultra rare disease fibrodysplasia ossificans progressiva (FOP), after EU advisors recommended against approval.

FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% ...